G
Gain Therapeutics
Preclinical stage biotech company developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary…
About Gain Therapeutics
Gain Therapeutics is a biotechnology company focused on developing innovative small molecule therapeutics for disorders with high unmet medical needs. Utilizing a combination of physics-based methods and artificial intelligence, Gain Therapeutics creates next-generation allosteric small molecules that can modulate proteins to restore or disrupt their function. These molecules can inhibit, activate, stabilize, destabilize, or degrade proteins based on the specific disease pathology. The company primarily serves the healthcare and pharmaceutical sectors, targeting conditions that currently lack effective treatments. Gain Therapeutics operates in the global biotechnology market and follows a business-to-business (B2B) model, partnering with other pharmaceutical companies for clinical development and commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from successful drug candidates.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2017
- Headquarters
- Lugano, Switzerland
- Listing
- IPO 2021
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 61.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, Horizon Europe, proteomics, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Jul 2025 | $7M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Jun 2024 | $11M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Gain Therapeutics is 21K monthly website visits, up 75% over the last three months. Gain Therapeutics's team declined 19.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Innosuisse
Series A2 investors entered at this stage
3B Future Health Fund
TiVentures
Series B and later1 investor entered at this stage
Minoryx Therapeutics
Other known investors1 additional known investor
- EBEmerging Technology Partners Biomedical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Gain Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gain Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.